Which factor is NOT typically considered a source of individual variability in drug response?

Which factor is NOT typically considered a source of individual variability in drug response?

• A. Genetic factors
• B. Disease
• C. Drug manufacturing quality
• D. Drug interactions

Answer: (C)

Interindividual differences in how a drug behaves and what effects it has come from factors that differ between people, especially those that affect how a drug is absorbed, distributed, metabolized, and excreted, or how it interacts with its targets. Genetic variations can change enzyme activity, receptor sensitivity, or transporter function, leading to faster or slower metabolism and different responses. Disease states, such as liver or kidney impairment, can alter clearance and tissue sensitivity, shifting both pharmacokinetics and pharmacodynamics. Concurrent drugs can cause interactions that inhibit or induce enzymes or transporters, altering drug levels or effects. Drug manufacturing quality, while essential for overall safety and potency, reflects product-level issues rather than inherent patient-specific differences. A faulty batch would tend to affect everyone using that product, not explain why individuals respond differently to the same dose. So manufacturing quality is not a typical source of interindividual variability in drug response.

Interindividual differences in how a drug behaves and what effects it has come from factors that differ between people, especially those that affect how a drug is absorbed, distributed, metabolized, and excreted, or how it interacts with its targets. Genetic variations can change enzyme activity, receptor sensitivity, or transporter function, leading to faster or slower metabolism and different responses. Disease states, such as liver or kidney impairment, can alter clearance and tissue sensitivity, shifting both pharmacokinetics and pharmacodynamics. Concurrent drugs can cause interactions that inhibit or induce enzymes or transporters, altering drug levels or effects.

Drug manufacturing quality, while essential for overall safety and potency, reflects product-level issues rather than inherent patient-specific differences. A faulty batch would tend to affect everyone using that product, not explain why individuals respond differently to the same dose. So manufacturing quality is not a typical source of interindividual variability in drug response.